Commonwealth Equity Services LLC Decreases Position in Johnson & Johnson (NYSE:JNJ)

Commonwealth Equity Services LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 1.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,714,119 shares of the company’s stock after selling 22,422 shares during the period. Johnson & Johnson makes up about 0.7% of Commonwealth Equity Services LLC’s portfolio, making the stock its 19th biggest holding. Commonwealth Equity Services LLC owned about 0.07% of Johnson & Johnson worth $303,793,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Family CFO Inc purchased a new position in Johnson & Johnson in the 4th quarter worth $26,000. Steward Financial Group LLC purchased a new position in Johnson & Johnson in the 4th quarter worth $34,000. Joseph P. Lucia & Associates LLC purchased a new position in Johnson & Johnson in the 1st quarter worth $38,000. Advocacy Wealth Management Services LLC raised its stake in Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after acquiring an additional 67 shares during the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth about $49,000. Hedge funds and other institutional investors own 68.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. The Goldman Sachs Group increased their price target on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Daiwa Capital Markets assumed coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating on the stock. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. UBS Group cut their price target on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Finally, Citigroup dropped their target price on Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Trading Down 1.6 %

JNJ stock opened at $171.79 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.14 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The stock has a market cap of $451.67 billion, a price-to-earnings ratio of 25.01, a PEG ratio of 3.29 and a beta of 0.59. The business’s 50-day moving average is $175.41 and its 200 day moving average is $174.52.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The business had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. During the same period last year, the company posted $2.48 EPS. The business’s revenue was up 3.0% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.63%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s payout ratio is presently 65.79%.

Insider Activity

In other news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.